{"analyses":[{"ciLowerLimit":"0.513","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.785","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Cox Proportional Hazard","paramValue":"0.63","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.34","upperLimit":"5.88","value":"5.59"},{"groupId":"OG001","lowerLimit":"2.86","upperLimit":"4.47","value":"3.98"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"226"}],"units":"Participants"}],"description":"PFS was defined as the time from randomization until progressive disease (PD) or death whichever occurred first. PD: At least a 20% increase in the sum of the longest diameters (SoD) of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 millimeters (mm). Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to single-agent MIRV at 6 mg/kg AIBW administered IV on Day 1 of Q3W.","id":"OG000","title":"Mirvetuximab Soravtansine"},{"description":"Participants randomized to IC chemotherapeutic agent calculated using BSA. Paclitaxel administered at 80 mg/m\\^2 as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan administered at 4 mg/m\\^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could have been administered at 1.25 mg/m\\^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin administered at 40 mg/m\\^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could have been administered as a 1-hour infusion.","id":"OG001","title":"Investigator's Choice (IC) Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"The ITT population included all participants randomized to the study, regardless of whether or not participants received study treatment (MIRV or IC Chemo).","reportingStatus":"POSTED","timeFrame":"From randomization until PD or death, whichever occurred first (up to approximately 36 months)","title":"Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1","type":"PRIMARY","unitOfMeasure":"months"}